{"id":43,"date":"2026-01-06T17:57:10","date_gmt":"2026-01-06T17:57:10","guid":{"rendered":"https:\/\/techtonicwebdesign.com\/works\/ansarylabs\/?page_id=43"},"modified":"2026-02-28T13:55:21","modified_gmt":"2026-02-28T13:55:21","slug":"minimal-residual-disease-mrd-analysis","status":"publish","type":"page","link":"https:\/\/techtonicwebdesign.com\/works\/ansarylabs\/%d8%a7%d9%84%d9%86%d8%b4%d8%b1%d8%a7%d8%aa-%d8%a7%d9%84%d8%a5%d8%ae%d8%a8%d8%a7%d8%b1%d9%8a%d8%a9\/minimal-residual-disease-mrd-analysis\/","title":{"rendered":"Minimal residual disease (MRD) analysis"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t

Minimal residual disease (MRD) analysis<\/h1>\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Ansary labs announces analysis of MRD analysis by multiparameter flow cytometry on bone marrow aspirate (BMA) sample in post therapy Acute Myeloid leukemia (AML), B-cell & T-cell Acute Lymphoblastic Leukemia (ALL) and multiple myeloma (MM).<\/p>

MRD was assessed using a standardized 10-color flow cytometry panel, employing a “different-from-normal” (DfN) and\/or “leukemia-associated immunophenotype” (LAIP) approach to identify aberrant cell populations. The analysis included a comprehensive panel of markers to track specific immunophenotypic deviations observed at the time of diagnosis and during follow-up, using normal precursor populations as internal controls. A minimum of 500 000 total events were acquired and analyzed to ensure a high level of sensitivity (typically approaching 10-4 or\u00a00.01%).\u00a0<\/p>

Interpretation of results<\/strong><\/p>

\u2022 MRD Negative: The level of residual disease detected is below the established limit of detection\/sensitivity of the assay (< 0.01% in ALL cases and < 0.1 in AML cases) and is considered negative.\u00a0<\/p>

\u2022 MRD Positive: A distinct aberrant cell population, consistent with the original leukemia immunophenotype, was detected at a level of (> 0.01% in ALL cases and > 0.1 in AML cases This indicates the presence of residual disease above the threshold of the assay.<\/p>

\u2022 The results from this MRD assessment should be considered in the context of the patient’s overall clinical status, treatment regimen, and other relevant laboratory findings (e.g., molecular genetics). The presence of MRD is a strong and independent prognostic factor and can inform clinical decision-making regarding further treatment and risk stratification.<\/p><\/div><\/div><\/article><\/div><\/div><\/div><\/div>

\u00a0<\/div><\/div><\/div><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Ansary labs announces analysis of MRD analysis by multiparameter flow cytometry on bone marrow aspirate (BMA) sample in post therapy Acute Myeloid leukemia (AML), B-cell & T-cell Acute Lymphoblastic Leukemia (ALL) and multiple myeloma (MM). MRD was assessed using a standardized 10-color flow cytometry panel, employing a “different-from-normal” (DfN) and\/or “leukemia-associated immunophenotype” (LAIP) approach to […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":37,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-43","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/techtonicwebdesign.com\/works\/ansarylabs\/wp-json\/wp\/v2\/pages\/43","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/techtonicwebdesign.com\/works\/ansarylabs\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/techtonicwebdesign.com\/works\/ansarylabs\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/techtonicwebdesign.com\/works\/ansarylabs\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/techtonicwebdesign.com\/works\/ansarylabs\/wp-json\/wp\/v2\/comments?post=43"}],"version-history":[{"count":7,"href":"https:\/\/techtonicwebdesign.com\/works\/ansarylabs\/wp-json\/wp\/v2\/pages\/43\/revisions"}],"predecessor-version":[{"id":865,"href":"https:\/\/techtonicwebdesign.com\/works\/ansarylabs\/wp-json\/wp\/v2\/pages\/43\/revisions\/865"}],"up":[{"embeddable":true,"href":"https:\/\/techtonicwebdesign.com\/works\/ansarylabs\/wp-json\/wp\/v2\/pages\/37"}],"wp:attachment":[{"href":"https:\/\/techtonicwebdesign.com\/works\/ansarylabs\/wp-json\/wp\/v2\/media?parent=43"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}